Please login to the form below

Not currently logged in
Email:
Password:

Embeda

This page shows the latest Embeda news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

FDA panel backs Pfizer and Teva abuse-resistant painkillers

Pfizer already sells an abuse-resistant formulation of morphine called Embeda, which uses the same naltrexone technology and was awarded an oral and intranasal abuse claim in 2014, but without an

Latest news

  • Opioid analgesics

    Pfizer's Embeda combines morphine and naltrexone in a single extended-release capsule. ... This, combined with the post-marketing data, suggest that Embeda is providing much-needed pain relief in this patient population without exposure to the risk of

  • Pfizer to buy King for $3.6bn

    sprains and bruises; and Embeda (morphine sulphate/ naltrexone hydrochloride), which was approved in August of this year as the first long-acting opioid that is designed to reduce drug liking and

  • King's profits hit by generic competition

    Its pain drug Embeda (morphine sulfate and naltrexone hydrochloride) is showing continued growth since it launched in September 2010 and reaped $15m during the second quarter.

  • Clouded vision

    EMBEDA (King Pharmaceuticals). Moderate to severe chronic pain . US. Oxycodone hydrochloride.

  • King Pharma announce unexpected profit

    The company is currently focusing on gaining regulatory approvals for its trio of opioid products for treating late-stage pain: Remoxy, an extended-release oxycodone drug, Embeda, an extended-release morphine

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics